Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels
| Autor: | Yasuhiro Hisanaga, Masashi Fujimori, Seiki Kiriyama, Makiko Takagi, Yasuhiro Sone, Akira Kanamori, Takashi Kumada, Takahiro Arakawa, Satoshi Nakano, Hiroyuki Atsumi, Makoto Tanikawa, Hidenori Toyoda |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Carcinoma Hepatocellular Adolescent Hepacivirus Hepatitis C virus medicine.disease_cause Gastroenterology Young Adult Reference Values Internal medicine medicine Humans Cumulative incidence Aged Retrospective Studies Aged 80 and over Hepatology biology medicine.diagnostic_test business.industry Incidence Liver Neoplasms Alanine Transaminase Bilirubin Hepatitis C Middle Aged Prognosis biology.organism_classification medicine.disease digestive system diseases Alanine transaminase Hepatocellular carcinoma Liver biopsy Carrier State biology.protein RNA Viral Female Liver cancer business Biomarkers |
| Zdroj: | Journal of Hepatology. 50:729-735 |
| ISSN: | 0168-8278 |
| Popis: | This study sought to identify the independent risk factors involved in the development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection who have normal alanine aminotransferase (ALT) levels.A total of 519 patients with average ALT integration values less than or equal to 40 IU/L over 10 years were included. Baseline ultrasound was done in all patients and 68 patients underwent liver biopsy at the start of this study. Factors associated with the cumulative incidence of HCC were determined.HCC occurred in 48 of 519 patients (9.2%). The following factors were significantly associated with the incidence of HCC: age65 years (adjusted hazard ratio: 2.006 [95% confidence interval: 1.078-3.733]), ALT20 IU/L (6.242 [1.499-25.987]), platelet count15.0x10(4)/m(3) (2.675 [1.407-5.085]), total bilirubin1.2mg/dL (2.798 [1.257-6.228]), ALP338 IU/L (2.486 [1.327-4.657]), and total albumin3.5g/dl (2.707 [1.177-6.223]). The 5- and 10-year cumulative incidences of HCC were 4.4% and 26.5% in patients with ALT20 IU/L and platelet count15.0x10(4)/m(3), respectively.High ALT level and low platelet count are closely associated with the development of hepatocarcinogenesis. Therefore, individuals within this group are candidates for antiviral therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect